Trexquant Investment LP Hutchmed (China) LTD Transaction History

Trexquant Investment LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$16.36 - $21.78 $344,050 - $458,033	-21,030 Reduced 43.71%	27,079 $463,000
Q1 2024 May 14, 2024	BUY	$12.08 - $18.56 $342,540 - $526,287	28,356 Added 143.55%	48,109 $808,000
Q4 2023 Feb 09, 2024	SELL	$16.25 - $20.23 $125,401 - $156,114	-7,717 Reduced 28.09%	19,753 $357,000
Q3 2023 Nov 13, 2023	SELL	$11.85 - $16.95 $84,087 - $120,277	-7,096 Reduced 20.53%	27,470 $465,000
Q2 2023 Aug 11, 2023	SELL	$10.78 - $17.73 $26,723 - $43,952	-2,479 Reduced 6.69%	34,566 $414,000
Q1 2023 May 15, 2023	SELL	$13.02 - $19.87 $296,790 - $452,936	-22,795 Reduced 38.09%	37,045 $482,000
Q4 2022 Feb 13, 2023	BUY	$7.65 - $15.51 $66,815 - $135,464	8,734 Added 17.09%	59,840 $884,000
Q3 2022 Nov 14, 2022	BUY	$8.63 - $15.52 $275,771 - $495,941	31,955 Added 166.86%	51,106 $453,000
Q2 2022 Aug 11, 2022	BUY	$8.59 - $20.77 $164,507 - $397,766	19,151 New	19,151 $242,000

6.88M

6.2K

1.1K

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $2.47B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

Stay updated on Trexquant Investment LP with notifications on news.